Clinical trials recruiting in Saint-Cloud, France

Phase breakdown

Conditions recruiting in Saint-Cloud, France

Recruiting trials in Saint-Cloud, France

• 68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)
  NCT06349512 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female
• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  NCT06966700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
  NCT06790693 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
  NCT07287098 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
  NCT07174336 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
  NCT05939414 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: Male
• COsegregation of VARiants in Panel of Genes
  NCT01689584 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
  NCT05973864 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
  NCT07237256 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female
• Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)
  NCT06659705 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• DESTINY Breast Respond HER2-(Ultra)Low Europe
  NCT05945732 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction
  NCT05255302 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female)
• ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
  NCT06195709 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)
  NCT06225505 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female
• Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR)
  NCT06459791 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
  NCT05512364 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)
  NCT03848052 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
  NCT03275311 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG
  NCT04790682 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
  NCT06625775 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.
  NCT05439005 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female
• Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures
  NCT05475366 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
  NCT05232916 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female)
• Skipping Hormone Therapy in Low-Risk Early Breast Cancer
  NCT07661927 · Phase: Phase 2 · Ages: 60 Years and older · Sex: Female
• Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
  NCT06496581 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: Male
• Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
  NCT07193394 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer
  NCT05955170 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TDHOME)
  NCT07491380 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Saint-Cloud, France?

29 recruiting trials have at least one study site in Saint-Cloud, France.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.